Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration

Basit Öğe Kaydı
dc.contributor.authorBakbak, Berker
dc.contributor.authorOzturk, Banu Turgut
dc.contributor.authorZamani, Ayse Gul
dc.contributor.authorGonul, Saban
dc.contributor.authorIyit, Neslihan
dc.contributor.authorGedik, Sansal
dc.contributor.authorYildirim, M. Selman
dc.date.accessioned2024-02-23T14:34:36Z
dc.date.available2024-02-23T14:34:36Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractPurpose: Genetic factors are known to influence the response to anti-vascular endothelial growth factor (VEGF) treatment in exudative age-related macular degeneration (AMD). The current study was conducted to investigate the association of Apolipoprotein E (ApoE) polymorphism with the treatment response to ranibizumab for exudative AMD.Methods: One hundred nine eyes (109 patients, 59.6% male, mean age 63.847.22 years) treated with intravitreal ranibizumab injections were included in the analysis. Smoking status and lesion type were recorded. Patients were categorized into three groups according to visual acuity (VA) change at 6 months after the first injection: VA loss >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Group 1); VA change between five ETDRS letters gain and loss (Group 2); VA improvement >5 ETDRS letters (Group 3). The association of ApoE gene polymorphisms with the three groups was evaluated.Results: Both smoking status and lesion type showed no significant association with VA change (p=0.12 and p=0.64, respectively). A lower frequency of 2 and a higher frequency of 4 were observed in Group 3 (2.9 and 25.7%, respectively). VA improvement with more than five ETDRS letters was significantly associated with the presence of the 4 genotype (p=0.01).Conclusions: This study demonstrated that carriers of the ApoE 4 polymorphism genotype show demonstrable improvement in VA after treatment with ranibizumab in exudative AMD. ApoE polymorphism identification may be used as a genetic screening to tailor individualized therapeutic approach for optimal treatment in neovascular AMD.en_US
dc.description.sponsorshipScientific Research Coordination Center of Selcuk University [BAP-13401104]en_US
dc.description.sponsorshipThe authors have no conflict of interest to declare. This study is supported by The Scientific Research Coordination Center of Selcuk University (BAP-13401104).en_US
dc.identifier.doi10.3109/02713683.2015.1067325
dc.identifier.endpage866en_US
dc.identifier.issn0271-3683
dc.identifier.issn1460-2202
dc.identifier.issue6en_US
dc.identifier.pmid26398858en_US
dc.identifier.scopus2-s2.0-84945242214en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage862en_US
dc.identifier.urihttps://doi.org/10.3109/02713683.2015.1067325
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15655
dc.identifier.volume41en_US
dc.identifier.wosWOS:000377931700016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofCurrent Eye Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAge-Related Macular Degenerationen_US
dc.subjectApoeen_US
dc.subjectApolipoprotein Een_US
dc.subjectRanibizumaben_US
dc.titleAssociation of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degenerationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu